Kronos Bio is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription.

Register for Details

For more details on financing and valuation for Kronos Bio, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Kronos Bio's ticker symbol?


What is Kronos Bio's stock price?

1.3 as of 9/29/23

Learn more about Kronos Bio

Forge green plus iconForge green minus icon

What is Kronos Bio funding to date?

Kronos Bio has raised $123MM to date.
Forge green plus iconForge green minus icon

When was Kronos Bio founded?

Kronos Bio was founded in 2017.
Updated on: Jun 12, 2022